Hologic, Inc. (NASDAQ:HOLX) – Investment analysts at William Blair upped their FY2018 earnings per share estimates for shares of Hologic in a research note issued on Thursday. William Blair analyst B. Weinstein now anticipates that the medical equipment provider will post earnings per share of $2.23 for the year, up from their previous estimate of $2.12. William Blair also issued estimates for Hologic’s FY2019 earnings at $2.49 EPS.

A number of other research firms have also weighed in on HOLX. Bank of America raised shares of Hologic from a “neutral” rating to a “buy” rating and set a $50.00 target price on the stock in a research note on Thursday, January 4th. BidaskClub lowered shares of Hologic from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 25th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $48.00 price target on shares of Hologic in a research report on Thursday, November 9th. Evercore ISI started coverage on shares of Hologic in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $50.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 price target on shares of Hologic in a research report on Friday. One analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $48.36.

Hologic (NASDAQ:HOLX) opened at $37.75 on Monday. The company has a quick ratio of 0.98, a current ratio of 1.25 and a debt-to-equity ratio of 0.87. Hologic has a 12 month low of $35.33 and a 12 month high of $46.80. The firm has a market cap of $10,438.97, a P/E ratio of 18.42, a price-to-earnings-growth ratio of 1.71 and a beta of 0.77.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.05. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The business had revenue of $791.10 million for the quarter, compared to analyst estimates of $785.80 million. During the same period last year, the company posted $0.52 EPS. The business’s revenue was up 7.7% on a year-over-year basis.

Several hedge funds have recently added to or reduced their stakes in the company. Employees Retirement System of Texas increased its holdings in Hologic by 80.0% in the 2nd quarter. Employees Retirement System of Texas now owns 18,000 shares of the medical equipment provider’s stock valued at $817,000 after purchasing an additional 8,000 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Hologic by 556.0% in the 2nd quarter. Janus Henderson Group PLC now owns 246,752 shares of the medical equipment provider’s stock valued at $11,197,000 after purchasing an additional 209,138 shares during the last quarter. Gotham Asset Management LLC acquired a new stake in Hologic in the 2nd quarter valued at approximately $1,870,000. Cubist Systematic Strategies LLC acquired a new stake in Hologic in the 2nd quarter valued at approximately $635,000. Finally, Raymond James Financial Services Advisors Inc. acquired a new stake in Hologic in the 2nd quarter valued at approximately $1,043,000. 93.84% of the stock is currently owned by hedge funds and other institutional investors.

In other news, VP Karleen Marie Oberton sold 1,023 shares of Hologic stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $39.84, for a total transaction of $40,756.32. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.88% of the stock is currently owned by insiders.

WARNING: This article was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://theolympiareport.com/2018/02/12/hologic-inc-holx-forecasted-to-earn-fy2018-earnings-of-2-23-per-share.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.